Report
Jake Strole
EUR 100.00 For Business Accounts Only

West Pharma Starts 2019 Ahead of Expectations; Raising FVE

Wide-moat West Pharmaceutical Services reported a strong start to its year with organic revenue expanding 11%, led by its high-value product portfolio that expanded nearly 20% on a reported basis, by our math. We'll probably bump up our $100 fair value estimate by a mid-single-digit percentage as we tweak our model to account for this better-than-expected growth. However, with the stock currently trading at over 40 times our 2019 adjusted earnings estimate, we have a hard time strongly recommend...
Underlying
West Pharmaceutical Services Inc.

West Pharmaceutical Services is a manufacturer in the design and production of containment and delivery systems for injectable drugs and healthcare products. The company's products include packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. The company's segments are: Proprietary Products, which provides packaging, containment and drug delivery products, analytical lab services and integrated solutions; and Contract-Manufactured Products, which is focused on the design, manufacture, and automated assembly of devices, for pharmaceutical, diagnostic, and medical device customers.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Jake Strole

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch